phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with Tachycardia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, M; Fang, Q; Guo, J; He, F; Peng, YL; Wang, R | 1 |
1 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Tachycardia
| Article | Year |
|---|---|
In vivo inhibition of neuropeptide FF agonism by BIBP3226, an NPY Y1 receptor antagonist.
Topics: Animals; Anti-Anxiety Agents; Arginine; Hypothermia; Male; Mice; Oligopeptides; Rats; Rats, Wistar; Receptors, Neuropeptide; Receptors, Neuropeptide Y; Tachycardia; Time Factors | 2006 |